KKR's $820M Investment Fuels Samsung SDS AI Expansion, Sending Group Shares Soaring 
Federal Judge Dismisses DOJ Lawsuit Attempting to Block Hawaii's Climate Case Against Oil Giants 
OpenAI's $20 Billion Cerebras Deal Signals Massive AI Infrastructure Push 
Japan to Subsidize Sony's Image Sensor Plant in Kumamoto with $380 Million 
Iran War Drives Asia's Plastic Crisis — and a Green Packaging Boom 
Anthropic CEO Meets Trump Officials to Discuss Powerful New AI Model Mythos 
TSMC Posts Record Q1 Profit Fueled by AI Chip Demand 
Uber Bets Big on Autonomous Vehicles with $10 Billion Commitment 
CATL Stock Hits Record High After Q1 2025 Earnings Surge 
NiSource Signs Long-Term Energy Deals with Alphabet and Amazon to Power Indiana Data Centers 
DEEPX Partners with Hyundai to Power Next-Gen AI Robots Ahead of IPO 
Netflix Q2 Profit Warning Sends Shares Tumbling as Reed Hastings Exits 
Pentagon Taps Auto Giants to Supercharge U.S. Weapons Production 
Federal Agencies Secretly Test Anthropic's AI Despite Trump Administration Ban 
CSN's Cement Unit Sale Could Exceed $2 Billion as Global Giants Circle 
Apple Wins ITC Ruling, Keeping Blood-Oxygen Feature on Apple Watch 
Elliott Investment Takes ~3% Stake in Daikin, Pushes for Buybacks and Strategic Overhaul 
 2016 World Congress - EconoTimes)
BURLINGTON, Mass., April 01, 2016 -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced that it will report results from the pivotal Phase 2b and Phase 3 clinical trials of its lead drug candidate Zilretta (also known as FX006) at the Osteoarthritis Research Society International (OARSI) 2016 World Congress at the RAI Amsterdam Convention Center in Amsterdam, The Netherlands, on Saturday, April 2 at 2:00 p.m. CET/9:00 a.m. EDT.
The presentation will be part of Concurrent Session 9 - OA Treatment - Structure and Pain with abstract presentations. The title of the scientific abstract is “Sustained and Profound Analgesic Benefits in People with Osteoarthritis of the Knee Using FX006, an Intra-articular Extended-Release Formulation of Triamcinolone Acetonide.”
Investor Contact David Carey Lazar Partners LTD T: 212-867-1768 [email protected] Media Contact Mariann Caprino TogoRun T: 917.242.1087 [email protected] Corporate Contact Fred Driscoll Chief Financial Officer Flexion Therapeutics, Inc. T: 781-305-7763 [email protected]
